Display options
Cite
Rosenthal E, Moyes K, Arnell C, et al. Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res Treat. 2015;151(1):233doi: 10.1007/s10549-015-3361-z.
Rosenthal, E., Moyes, K., Arnell, C., Evans, B., & Wenstrup, R. J. (2015). Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast cancer research and treatment, 151(1), 233. https://doi.org/10.1007/s10549-015-3361-z
Rosenthal, Eric, et al. "Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry." Breast cancer research and treatment vol. 151,1 (2015): 233. doi: https://doi.org/10.1007/s10549-015-3361-z
Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ. Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res Treat. 2015 May;151(1):233. doi: 10.1007/s10549-015-3361-z. PMID: 25850536.
Copy Download .nbib Format: NLM
Share it on

Breast Cancer Res Treat. 2015 May;151(1):233. doi: 10.1007/s10549-015-3361-z.

Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.

Breast cancer research and treatment

Eric Rosenthal, Kelsey Moyes, Christopher Arnell, Brent Evans, Richard J Wenstrup

Affiliations

  1. Myriad Genetic Laboratories, Inc., 320 Wakara Way, Salt Lake City, UT, 84108, USA, [email protected].

PMID: 25850536 DOI: 10.1007/s10549-015-3361-z

Abstract

In Table 2 of the original publication, the HGVS and legacy nomenclature were mismatched and the HGVS nomenclature did not correlate with data listed in the table. The corrected table is listed below.

Publication Types